{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:54:28Z","timestamp":1790459668810,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,2]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>A CD19\/CD3 single-chain Fv-Fc bsAb mediated potent killing of CLL cells by autologous T cells in vitro and in vivo. bsAb-mediated cytotoxicity was enhanced by prior therapy with ibrutinib and extended to ibrutinib-resistant disease.<\/jats:p>","DOI":"10.1182\/blood-2018-02-830992","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T13:21:28Z","timestamp":1525872088000},"page":"521-532","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":104,"title":["A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era"],"prefix":"10.1182","volume":"132","author":[{"given":"Hannah R.","family":"Robinson","sequence":"first","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika M.","family":"Cook","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cydney","family":"Nichols","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman L.","family":"Dadashian","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chingiz","family":"Underbayev","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E. M.","family":"Herman","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Keyvanfar","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-4729","authenticated-orcid":false,"given":"Clare","family":"Sun","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivasubramanian","family":"Baskar","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rader","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111911082735000_B1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111911082735000_B2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111911082735000_B3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111911082735000_B4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111911082735000_B5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"16","key":"2019111911082735000_B6","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2019111911082735000_B7","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2019111911082735000_B8","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019111911082735000_B9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111911082735000_B10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"2019111911082735000_B11","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"2019111911082735000_B12","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111911082735000_B13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111911082735000_B14","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor\u2013microenvironment interactions by ibrutinib \u2013 findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111911082735000_B15","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111911082735000_B16","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"21","key":"2019111911082735000_B17","doi-asserted-by":"crossref","first-page":"34661","DOI":"10.18632\/oncotarget.16148","article-title":"Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number","volume":"8","author":"Podhorecka","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"2019111911082735000_B18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2019111911082735000_B19","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111911082735000_B20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111911082735000_B21","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111911082735000_B22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111911082735000_B23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.leu.2402890","article-title":"Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct","volume":"17","author":"L\u00f6ffler","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"2019111911082735000_B24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"2019111911082735000_B25","doi-asserted-by":"crossref","first-page":"17943","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"287","key":"2019111911082735000_B26","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"issue":"11","key":"2019111911082735000_B27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"2019111911082735000_B28","article-title":"Potent and selective antitumor activity of a T-cell engaging bispecific antibody targeting a membrane-proximal epitope of ROR1","author":"Qi","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"2019111911082735000_B29","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Herman","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019111911082735000_B30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"key":"2019111911082735000_B31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic Fc engineering \u2013 modulation of IgG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"issue":"3","key":"2019111911082735000_B32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jmb.2009.06.048","article-title":"Structure of the murine unglycosylated IgG1 Fc fragment","volume":"391","author":"Feige","year":"2009","journal-title":"J Mol Biol"},{"issue":"6","key":"2019111911082735000_B33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"issue":"20","key":"2019111911082735000_B34","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111911082735000_B35","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1158\/0008-5472.CAN-14-2030","article-title":"Harnessing the fc\u03bc receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia","volume":"74","author":"Vire","year":"2014","journal-title":"Cancer Res"},{"issue":"8","key":"2019111911082735000_B36","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","article-title":"T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3- bispecific single-chain antibody construct","volume":"170","author":"Dreier","year":"2003","journal-title":"J Immunol"},{"issue":"23","key":"2019111911082735000_B37","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"24","key":"2019111911082735000_B38","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111911082735000_B39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111911082735000_B40","doi-asserted-by":"crossref","first-page":"e86288","DOI":"10.1172\/jci.insight.86288","article-title":"Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process","volume":"1","author":"Patten","year":"2016","journal-title":"JCI Insight"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/5\/521\/1466900\/blood830992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/5\/521\/1466900\/blood830992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T13:57:50Z","timestamp":1574171870000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/5\/521\/39398\/A-CD19CD3-bispecific-antibody-for-effective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,8,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-02-830992","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]}}}